UA102812C2 - Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применение - Google Patents

Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применение

Info

Publication number
UA102812C2
UA102812C2 UAA200904020A UAA200904020A UA102812C2 UA 102812 C2 UA102812 C2 UA 102812C2 UA A200904020 A UAA200904020 A UA A200904020A UA A200904020 A UAA200904020 A UA A200904020A UA 102812 C2 UA102812 C2 UA 102812C2
Authority
UA
Ukraine
Prior art keywords
antibodies
generating active
resistance
tumor
resistant
Prior art date
Application number
UAA200904020A
Other languages
English (en)
Ukrainian (uk)
Inventor
Лилиан Гетш
Александра ЖУАННО
Original Assignee
Пьер Фабр Медикамент
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикамент filed Critical Пьер Фабр Медикамент
Publication of UA102812C2 publication Critical patent/UA102812C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к применению измельченного гомогената и/или суспензии, и/или клеточного лизата, которые происходят из опухоли, устойчивой по меньшей мере к одному противоопухолевому соединению, с целью иммунизации и созданияантитела или одного из его функциональных фрагментов, направленного против опухолевого антигена, который специфично экспрессируется на поверхности указанной резистентной опухоли, а также их применению для лечения рака.
UAA200904020A 2006-09-28 2007-09-27 Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применение UA102812C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (1)

Publication Number Publication Date
UA102812C2 true UA102812C2 (ru) 2013-08-27

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904020A UA102812C2 (ru) 2006-09-28 2007-09-27 Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применение

Country Status (21)

Country Link
US (2) US8241646B2 (ru)
EP (4) EP2081592B1 (ru)
JP (1) JP5774276B2 (ru)
KR (1) KR101504770B1 (ru)
CN (1) CN101516394B (ru)
AR (1) AR063061A1 (ru)
AU (1) AU2007312437C1 (ru)
BR (1) BRPI0717246A2 (ru)
CA (1) CA2663561A1 (ru)
FR (1) FR2906533B1 (ru)
IL (1) IL197790A (ru)
MA (1) MA30954B1 (ru)
MX (1) MX2009003245A (ru)
NO (1) NO20091613L (ru)
NZ (1) NZ576420A (ru)
RU (1) RU2515904C2 (ru)
TN (1) TN2009000102A1 (ru)
TW (1) TWI516276B (ru)
UA (1) UA102812C2 (ru)
WO (1) WO2008046724A1 (ru)
ZA (1) ZA200902697B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
WO2011066417A2 (en) * 2009-11-24 2011-06-03 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
CN106794194A (zh) * 2014-06-30 2017-05-31 中央研究院 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AR104413A1 (es) * 2015-04-27 2017-07-19 Pf Medicament Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
TWI716400B (zh) * 2015-04-27 2021-01-21 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途（二）
CN108290936B (zh) * 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
KR950700061A (ko) * 1992-02-06 1995-01-16 스티븐 엘. 네스비트 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes)
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
SI1461359T1 (sl) 2002-01-18 2007-06-30 Pf Medicament Nova anti IGF-IR protitelesa in njihova uporaba
WO2004026293A2 (en) 2002-09-20 2004-04-01 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
JP2008500269A (ja) * 2003-10-08 2008-01-10 イーバイオサイエンス 天然免疫グロブリン結合試薬とその作製及び使用方法
PT1720540E (pt) 2004-02-18 2008-09-10 Gpc Biotech Ag Métodos de tratamento de tumores resistentes ou refractários
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Also Published As

Publication number Publication date
US8241646B2 (en) 2012-08-14
US20130028835A1 (en) 2013-01-31
KR20090057469A (ko) 2009-06-05
KR101504770B1 (ko) 2015-03-20
MX2009003245A (es) 2009-07-07
CA2663561A1 (en) 2008-04-24
CN101516394B (zh) 2014-07-30
NZ576420A (en) 2012-05-25
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
EP2494984B1 (en) 2017-01-04
US8808667B2 (en) 2014-08-19
CN101516394A (zh) 2009-08-26
TN2009000102A1 (en) 2010-08-19
FR2906533B1 (fr) 2013-02-22
EP2494984A1 (en) 2012-09-05
IL197790A (en) 2016-10-31
EP2081592B1 (en) 2016-01-13
AR063061A1 (es) 2008-12-23
IL197790A0 (en) 2011-08-01
AU2007312437A1 (en) 2008-04-24
NO20091613L (no) 2009-06-26
JP2010504743A (ja) 2010-02-18
EP2491945B1 (en) 2016-12-07
US20100146650A1 (en) 2010-06-10
EP2491945A1 (en) 2012-08-29
ZA200902697B (en) 2010-04-28
EP2491945B9 (en) 2017-03-08
FR2906533A1 (fr) 2008-04-04
HK1131063A1 (en) 2010-01-15
BRPI0717246A2 (pt) 2013-10-08
JP5774276B2 (ja) 2015-09-09
WO2008046724A1 (en) 2008-04-24
TW200822934A (en) 2008-06-01
AU2007312437B2 (en) 2014-01-23
AU2007312437C1 (en) 2014-04-10
RU2009114682A (ru) 2010-11-20
EP2497491A1 (en) 2012-09-12
MA30954B1 (fr) 2009-12-01
EP2497491B1 (en) 2017-03-01
EP2081592A1 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
UA102812C2 (ru) Способ генерирования активных антител к антигену устойчивости, антитела, полученные этим способом, и их применение
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
EP4427805A3 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
WO2012047317A3 (en) Tumor specific antibodies and uses therefor
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
NZ604003A (en) Monoclonal antibodies against her2
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
SG170080A1 (en) Human monoclonal antibodies to o8e
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
WO2008067283A3 (en) Ovr110 antibody compositions and methods of use
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2004005470A3 (en) Antibodies to non-shed muc1 and muc16, and uses thereof
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
EP1996716A4 (en) MANIPULATED ANTI-PROSTATE STEAM CELL RESPONSIVES (PSCA) ANTIBODIES FOR CANCER TARGETING
IN2014MN01879A (ru)
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
WO2009140177A3 (en) Anti-fn14 antibodies and uses thereof
UA103004C2 (ru) Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1